. .. Membranaires, 61 5.5.1. Comparaison des différentes recommandations concernant le diagnostic de la TIH, Mesure de la génération de microparticules plaquettaires

.. .. Surveillance-de-la-numération-plaquettaire,

.. .. Traitements, 1.5. Les anticoagulants oraux directs (AOD)

T. .. En,

J. Mclean, The Discovery of Heparin, Circulation. janv, vol.19, issue.1, pp.75-83, 1959.

R. E. Weismann, Arterial Embolism Occurring During Systemic Heparin Therapy, Arch Surg. 1 févr, vol.76, issue.2, p.219, 1958.

A. Cuker, Heparin-induced thrombocytopenia: present and future, J Thromb Thrombolysis. avr, vol.31, issue.3, pp.353-66, 2011.

N. Martel, J. Lee, and P. S. Wells, Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis, Blood, vol.15, issue.8, pp.2710-2715, 2005.

J. L. Francis, G. J. Palmer, R. Moroose, and A. Drexler, Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. The Annals of Thoracic Surgery, janv, vol.75, issue.1, pp.17-22, 2003.

G. Gihp, , 2019.

G. Oliveira, Incidence and Prognostic Significance of Thrombocytopenia in Patients Treated With Prolonged Heparin Therapy, Arch Intern Med. 14 janv, vol.168, issue.1, p.94, 2008.

T. E. Warkentin, J. Sheppard, C. S. Sigouin, T. Kohlmann, P. Eichler et al., Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia, Blood, vol.108, issue.9, pp.2937-2978, 2006.

P. D. Stein, R. D. Hull, F. Matta, A. Y. Yaekoub, and J. Liang, Incidence of Thrombocytopenia in Hospitalized Patients with Venous Thromboembolism. The American Journal of Medicine, vol.122, pp.919-949, 2009.

T. E. Warkentin, J. Sheppard, P. Horsewood, P. J. Simpson, J. C. Moore et al., Impact of the patient population on the risk for heparin-induced thrombocytopenia, vol.96, p.7, 2000.

A. Cuker and D. B. Cines, How I treat heparin-induced thrombocytopenia, Blood. 8 mars, vol.119, issue.10, pp.2209-2227, 2012.

D. Sagaram, Z. Siddiq, A. Eisenberger, C. Ananth, J. Wright et al., Heparin-Induced Thrombocytopenia during Obstetric Hospital Admissions, Amer J Perinatol. juill, vol.35, issue.09, pp.898-903, 2018.

E. A. Obeng, K. M. Harney, T. Moniz, A. Arnold, E. J. Neufeld et al., Pediatric Heparin-Induced Thrombocytopenia: Prevalence, Thrombotic Risk, and Application of the 4Ts Scoring System, The Journal of Pediatrics. janv, 2015.

C. Pötschke, S. Selleng, B. M. Bröker, and A. Greinacher, Heparin-induced thrombocytopenia: further evidence for a unique immune response. Blood, vol.120, pp.4238-4283, 2012.

T. E. Warkentin, Temporal Aspects of Heparin-Induced Thrombocytopenia, The New England Journal of Medicine, vol.7, 2001.

A. Greinacher, T. Kohlmann, U. Strobel, J. Sheppard, and T. E. Warkentin, The temporal profile of the anti-PF4/heparin immune response, Blood. 14 mai, vol.113, issue.20, pp.4970-4976, 2009.

T. E. Warkentin, J. Sheppard, J. C. Moore, R. J. Cook, and J. G. Kelton, Studies of the immune response in heparin-induced thrombocytopenia, Blood. 14 mai, vol.113, issue.20, pp.4963-4972, 2009.

M. B. Zucker and I. R. Katz, Platelet Factor 4: Production, Structure, and Physiologic and Immunologic Action, Experimental Biology and Medicine, vol.198, issue.2, pp.693-702, 1991.

J. Hirsh and R. Raschke, Heparin and Low-Molecular-Weight Heparin, Chest. sept, vol.126, issue.3, pp.188-203, 2004.

J. Hirsh, T. E. Warkentin, S. G. Shaughnessy, S. S. Anand, J. L. Halperin et al., Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety, Chest. janv, vol.119, issue.1, pp.64-94, 2001.

I. Elalamy, Héparines : structure, propriétés pharmacologiques et activités, EMC -Hématologie. janv, vol.5, issue.3, pp.1-12, 2010.

D. A. Lane, J. Denton, A. M. Flynn, L. Thunberg, and U. Lindahl, Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4, Biochemical Journal. 15 mars, vol.218, issue.3, pp.725-757, 1984.

G. M. Arepally, Heparin-induced thrombocytopenia, vol.129, p.10, 2017.

L. Rauova, M. Poncz, S. E. Mckenzie, M. P. Reilly, G. Arepally et al., Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia, Blood. 1 janv, vol.105, issue.1, pp.131-139, 2005.

T. E. Warkentin, How I Diagnose and Manage HIT, Hematology. 10 déc, vol.2011, issue.1, pp.143-152, 2011.

Y. Gruel, J. Rollin, D. Leroux, and C. Pouplard, Les thrombocytopénies induites par l'héparine : données récentes. La Revue de Médecine Interne, mars, vol.35, issue.3, pp.174-82, 2014.

B. H. Chong, I. Fawaz, C. N. Chesterman, and M. C. Berndt, Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets, Br J Haematol, vol.73, issue.2, pp.235-275, 1989.

J. R. Fitzgerald, T. J. Foster, and D. Cox, The interaction of bacterial pathogens with platelets, Nat Rev Microbiol. juin, vol.4, issue.6, pp.445-57, 2006.

J. Rollin, C. Pouplard, and Y. Gruel, Rollin2015 increased risk of thrombosis in FcgRIIA 131RR patients with TIH due to defective control of platelet activation by plasma IgG2, Thromb Haemost. sept, vol.116, issue.11, 2016.

J. Rollin, C. Pouplard, M. Gratacap, D. Leroux, M. May et al., Polymorphisms of protein tyrosine phosphatase CD148 influence Fc?RIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia, Blood. 9 août, vol.120, issue.6, pp.1309-1325, 2012.

D. Madeeva, D. B. Cines, M. Poncz, and L. Rauova, Role of monocytes and endothelial cells in heparin-induced thrombocytopenia, Thromb Haemost. sept, vol.116, issue.11, pp.806-818, 2016.

C. Pouplard, S. Iochmann, R. B. Herault, O. Colombat, P. Amiral et al., Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia, Blood. 15 mai, vol.97, issue.10, pp.3300-3302, 2001.

Z. Xiao, G. P. Visentin, K. M. Dayananda, and S. Neelamegham, Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion, Blood. 15 août, vol.112, issue.4, pp.1091-100, 2008.

M. Blank, Y. Shoenfeld, S. Tavor, S. Praprotnik, M. C. Boffa et al., Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells, International Immunology. févr, vol.14, issue.2, pp.121-130, 2002.

A. Cuker, Management of the multiple phases of heparin-induced thrombocytopenia

, Thromb Haemost. sept, vol.116, issue.11, pp.835-877, 2016.

G. Gihp, , 2019.

T. E. Warkentin, Drug-Induced Immune-Mediated Thrombocytopenia -From Purpura to Thrombosis, N Engl J Med. mars, vol.356, issue.9, pp.891-894, 2007.

T. E. Warkentin, R. S. Roberts, J. Hirsh, and J. G. Kelton, An Improved Definition of Immune Heparin-Induced Thrombocytopenia in Postoperative Orthopedic Patients, Arch Intern Med, vol.163, issue.20, p.2518, 2003.

T. E. Warkentin, Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia, Thromb Haemost. sept, vol.116, issue.11, pp.813-835, 2016.

A. Padmanabhan, C. G. Jones, D. W. Bougie, B. R. Curtis, J. G. Mcfarland et al.,

. Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis, Blood. 1 janv, vol.125, issue.1, pp.155-61, 2015.

T. E. Warkentin and J. G. Kelton, A 14-year study of heparin-induced thrombocytopenia. The American Journal of Medicine, vol.101, pp.502-509, 1996.

T. Tassava and T. E. Warkentin, Non-injection-site necrotic skin lesions complicating postoperative heparin thromboprophylaxis: Skin necrosis distant from heparin injection sites, Am J Hematol. août, vol.90, issue.8, pp.747-50, 2015.

T. E. Warkentin, R. S. Roberts, J. Hirsh, and J. G. Kelton, Heparin-Induced Skin Lesions and Other Unusual Sequelae of the Heparin-Induced Thrombocytopenia Syndrome, Chest. mai, vol.127, issue.5, pp.1857-61, 2005.

T. E. Warkentin, E. L. Safyan, and L. Linkins, Heparin-Induced Thrombocytopenia Presenting as Bilateral Adrenal Hemorrhages, N Engl J Med. 29 janv, vol.372, issue.5, pp.492-496, 2015.

A. Cuker, P. A. Gimotty, M. A. Crowther, and T. E. Warkentin, Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood, vol.15, 2012.

W. Pierce, J. Mazur, C. Greenberg, J. Mueller, J. Foster et al., Evaluation of Heparininduced Thrombocytopenia (HIT) Laboratory Testing and the 4Ts Scoring System in the Intensive Care Unit, vol.43, p.7, 2013.

M. Wanat, K. Fitousis, J. Hall, and L. Rice, PF4/Heparin Antibody Testing and Treatment of Heparin-Induced Thrombocytopenia in the Intensive Care Unit, Clin Appl Thromb Hemost. juin, vol.19, issue.3, pp.297-302, 2013.

A. Cuker, G. Arepally, M. A. Crowther, L. Rice, F. Datko et al., The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion: HEP Score, Journal of Thrombosis and Haemostasis. déc, vol.8, issue.12, pp.2642-50, 2010.

A. M. Pishko, S. Fardin, D. S. Lefler, K. Paydary, R. Vega et al., Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia. Blood Advances, vol.2, pp.3155-62, 2018.

L. Louet, A. Boutouyrie, P. Alhenc-gelas, M. , L. Beller et al., Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass, J Thromb Haemost, vol.2, issue.11, pp.1882-1890, 2004.

T. E. Warkentin and A. Greinacher, Heparin-induced thrombocytopenia and cardiac surgery. The Annals of Thoracic Surgery, août, vol.76, issue.2, pp.638-686, 2003.

J. Day and K. M. Taylor, The systemic inflammatory response syndrome and cardiopulmonary bypass, International Journal of Surgery, vol.3, issue.2, pp.129-169, 2005.

T. E. Warkentin, A. Greinacher, Y. Gruel, R. H. Aster, and B. H. Chong, Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis: Laboratory testing for heparin-induced thrombocytopenia, on behalf of the scientific and standardization committee of the international society on thrombosis and haemostasis, vol.9, pp.2498-500, 2011.

M. Nagler and T. Bakchoul, Clinical and laboratory tests for the diagnosis of heparin-induced thrombocytopenia, Thromb Haemost. sept, vol.116, issue.11, pp.823-857, 2016.

D. E. Arnaud, . Des, and . De-depistage, , p.11

J. Marler, Consequences of treating false positive heparin-induced thrombocytopenia, p.3

H. D. Husseinzadeh, P. A. Gimotty, A. M. Pishko, M. Buckley, T. E. Warkentin et al., Diagnostic accuracy of IgG-specific versus polyspecific enzyme-linked immunoassays in heparininduced thrombocytopenia: a systematic review and meta-analysis, J Thromb Haemost. juin, vol.15, issue.6, pp.1203-1215, 2017.

S. Baroletti, S. Hurwitz, N. Conti, J. Fanikos, G. Piazza et al., Thrombosis in Suspected Heparin-induced Thrombocytopenia Occurs More Often with High Antibody Levels, The American Journal of Medicine. janv, vol.125, issue.1, pp.44-53, 2012.

S. Y. Kim, H. K. Kim, K. S. Han, I. Kim, S. Yoon et al., Utility of ELISA Optical Density Values and Clinical Scores for the Diagnosis of and Thrombosis Prediction in Heparininduced Thrombocytopenia, Korean J Lab Med, vol.31, issue.1, p.1, 2011.

B. M. Weiss, N. M. Shumway, R. S. Howard, L. K. Ketchum, and T. J. Reid, Optical density values correlate with the clinical probability of heparin induced thrombocytopenia, J Thromb Thrombolysis. déc, vol.26, issue.3, pp.243-250, 2008.

J. I. Zwicker, L. Uhl, W. Huang, B. H. Shaz, and K. A. Bauer, Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia, J Thromb Haemost. déc, vol.2, issue.12, pp.2133-2140, 2004.

T. E. Warkentin, J. I. Sheppard, J. C. Moore, C. S. Sigouin, and J. G. Kelton, Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays, Journal of Thrombosis and Haemostasis. août, vol.6, issue.8, pp.1304-1316, 2008.

C. M. Chan, C. J. Woods, T. E. Warkentin, J. Sheppard, and A. F. Shorr, The Role for Optical Density in Heparin-Induced Thrombocytopenia, Chest. juill, 2015.

M. Pearson, C. Nadeau, and N. Blais, Correlation of ELISA Optical Density With Clinical Diagnosis of Heparin-Induced Thrombocytopenia: A Retrospective Study of 104 Patients With Positive Anti-PF4/Heparin ELISA, Clin Appl Thromb Hemost. mai, vol.20, issue.4, pp.349-54, 2014.

N. L. Whitlatch, D. F. Kong, A. D. Metjian, G. M. Arepally, and T. L. Ortel, Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia, Blood, vol.9, issue.10, pp.1761-1767, 2010.

G. Zheng, M. B. Streiff, C. M. Takemoto, J. Bynum, E. Gelwan et al., The Clinical Utility of the Heparin Neutralization Assay in the Diagnosis of Heparin-Induced Thrombocytopenia, Clin Appl Thromb Hemost. juill, vol.24, issue.5, pp.749-54, 2018.

K. Althaus, U. Strobel, T. E. Warkentin, and A. Greinacher, Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay, Thrombosis Research. sept, vol.128, issue.3, pp.256-60, 2011.

L. Sun, P. A. Gimotty, S. Lakshmanan, and A. Cuker, Diagnostic accuracy of rapid immunoassays for heparin-induced thrombocytopenia: A systematic review and meta-analysis, Thromb Haemost, vol.115, issue.05, 2016.

L. Alberio, S. Kimmerle, A. Baumann, B. M. Taleghani, F. D. Biasiutti et al., Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia, The American Journal of Medicine. mai, vol.114, issue.7, pp.528-564, 2003.

V. Nellen, I. Sulzer, G. Barizzi, B. Lammle, and L. Alberio, Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients, Haematologica. 1 janv, vol.97, issue.1, pp.89-97, 2012.

E. Strobel, Use of the ID-PaGIA Heparin/PF4 Antibody Test as a screening test for heparin/platelet factor 4 antibodies. Blood Transfusion, p.28, 2016.

D. Sur,

I. Choque and . Advsticexperthit_,

U. Sachs, J. Hesberg, S. Santoso, G. Bein, and T. Bakchoul, Evaluation of a new nanoparticlebased lateral-flow immunoassay for the exclusion of heparin-induced thrombocytopenia (HIT)

, Thromb Haemost, vol.106, issue.12, pp.1197-202, 2011.

A. Biosciences, PIFA® Heparin / Platelet Factor 4 Rapid Assay, p.4

D. M. Andrews, G. F. Cubillos, S. K. Paulino, D. L. Seckinger, and D. H. Kett, Prospective observational evaluation of the particle immunofiltration anti-platelet factor 4 rapid assay in MICU patients with thrombocytopenia, Crit Care, vol.17, issue.4, p.143, 2013.

F. B. Compton, R. Alrabeh, L. Q. Nguyen, E. Nedelcu, A. Wahed et al., PIFA PLUSS P4 Assay for Screening of Heparin-Induced Thrombocytopenia, vol.5, 2018.

M. Nagler, L. M. Bachmann, H. Ten-cate, and A. Cate-hoek, Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis, Blood. 4 févr, vol.127, issue.5, pp.546-57, 2016.

|. Acl-acustar and F. Werfen-en,

. Disponible, A. Black, S. Heimerl, L. Oertli, W. Wilczek et al., Implementation of a rapid HIT immunoassay at a university hospital -Retrospective analysis of HIT laboratory orders in patients with thrombocytopenia, Thrombosis Research, vol.158, pp.65-70, 2017.

T. E. Warkentin, J. Sheppard, L. Linkins, D. M. Arnold, and I. Nazy, High sensitivity and specificity of an automated IgG-specific chemiluminescence immunoassay for diagnosis of HIT, Blood. 20 sept, vol.132, issue.12, pp.1345-1354, 2018.

K. Althaus, G. Hron, U. Strobel, R. Abbate, A. Rogolino et al., Evaluation of automated immunoassays in the diagnosis of heparin induced thrombocytopenia, Thrombosis Research. mars, vol.131, issue.3, pp.85-90, 2013.

Y. Jourdy, C. Nougier, L. Rugeri, J. C. Bordet, F. Sobas et al., Prospective evaluation of automatized PF4/heparin immunoassays HemosIL HIT-ab (PF4-H) for the diagnosis of heparininduced thrombocytopenia, Int Jnl Lab Hem. avr, vol.37, issue.2, pp.244-52, 2015.

T. E. Warkentin, J. Sheppard, L. Linkins, D. M. Arnold, and I. Nazy, Performance characteristics of an automated latex immunoturbidimetric assay [HemosIL ® HIT-Ab (PF4-H) ] for the diagnosis of immune heparin-induced thrombocytopenia, Thrombosis Research. mai, vol.153, pp.108-125, 2017.

S. Selleng, K. Selleng, S. Friesecke, M. Gründling, S. Kuhn et al., Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study, J Thromb Thrombolysis. janv, vol.39, issue.1, pp.60-67, 2015.

T. E. Warkentin, Laboratory diagnosis of heparin-induced thrombocytopenia, p.11

T. Bakchoul, H. Zöllner, and A. Greinacher, Current insights into the laboratory diagnosis of HIT, Int Jnl Lab Hem. juin, vol.36, issue.3, pp.296-305, 2014.

V. Minet, J. Dogné, and F. Mullier, Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review, p.24, 2017.

T. E. Warkentin, D. M. Arnold, I. Nazi, and J. G. Kelton, The platelet serotonin-release assay: Serotonin-Release Assay, Am J Hematol. juin, vol.90, issue.6, pp.564-72, 2015.

G. Gobbi, P. Mirandola, P. L. Tazzari, F. Ricci, L. Caimi et al., Flow cytometry detection of serotonin content and release in resting and activated platelets, Br J Haematol. juin, vol.121, issue.6, pp.892-898, 2003.

J. Harenberg, G. Huhle, G. Ch, L. C. Wang, M. Feuring et al., Determination of serotonin release from platelets by enzyme immunoassay in the diagnosis of heparin-induced thrombocytopenia, Br J Haematol. avr, vol.109, issue.1, pp.182-188, 2000.

S. Koch, J. Harenberg, M. Ödel, H. Schmidt-gayk, S. Walch et al., Development of a High-Pressure Liquid Chromatography Method for Diagnosis of Heparin-Induced Thrombocytopenia. :5. 98. Sono-Koree NK, Int Jnl Lab Hem. févr, vol.38, issue.1, pp.72-80, 2016.

E. J. Favaloro, Hemostasis and thrombosis: methods and protocols, 2017.

I. Elalamy, V. Gkalea, G. Gerotziafas, H. Ketatni, and M. Hatmi, The usefulness of platelet function evaluation in clinical practice, Annales de biologie clinique, vol.71, issue.S1, pp.47-57, 2013.

M. Morel-kopp, F. Mullier, V. Gkalea, T. Bakchoul, V. Minet et al., Heparininduced multi-electrode aggregometry method for heparin-induced thrombocytopenia testing: communication from the SSC of the ISTH, J Thromb Haemost. déc, vol.14, issue.12, pp.2548-52, 2016.

V. Minet, N. Bailly, J. Douxfils, J. C. Osselaer, J. Laloy et al., Assessment of the performances of AcuStar HIT and the combination with heparin-induced multiple electrode aggregometry: A retrospective study, Thrombosis Research. sept, vol.132, issue.3, pp.352-361, 2013.

M. Morel-kopp, C. Tan, T. A. Brighton, S. Mcrae, R. Baker et al., Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: Results of a large Australian study, Thromb Haemost, vol.107, issue.03, pp.575-83, 2012.

E. Mali?ev, M. Kozak, and P. Ro?man, Evaluation of a flow cytometric assay for the confirmation of heparin-induced thrombocytopenia, Int Jnl Lab Hem. juin, vol.38, issue.3, pp.240-245, 2016.

F. Mullier, V. Minet, N. Bailly, B. Devalet, J. Douxfils et al., Platelet microparticle generation assay: A valuable test for immune heparin-induced thrombocytopenia diagnosis, Thrombosis Research. juin, vol.133, issue.6, pp.1068-73, 2014.

B. Tardy-poncet, M. Piot, C. Chapelle, G. France, L. Campos et al., Thrombin generation and heparin-induced thrombocytopenia, Journal of Thrombosis and Haemostasis. sept, vol.7, issue.9, pp.1474-81, 2009.
URL : https://hal.archives-ouvertes.fr/ujm-00439714

A. Cuker, A. H. Rux, J. L. Hinds, B. A. Konkle, G. M. Arepally et al., Novel diagnostic assays for heparin-induced thrombocytopenia, vol.121, p.7, 2013.

I. Nazi, D. M. Arnold, J. W. Smith, P. Horsewood, J. C. Moore et al., Fc?RIIa proteolysis as a diagnostic biomarker for heparin-induced thrombocytopenia, J Thromb Haemost. juin, vol.11, issue.6, pp.1146-53, 2013.

H. Watson, S. Davidson, and D. Keeling, Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition, Br J Haematol, 2012.

A. Cuker, G. M. Arepally, B. H. Chong, D. B. Cines, A. Greinacher et al., American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparininduced thrombocytopenia. Blood Advances, vol.2, pp.3360-92, 2018.

C. Pdf,

D. Sur,

H. N. Magnani and A. Gallus, A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004, Thromb Haemost. juin, vol.95, issue.6, pp.967-81, 2006.

B. Tardy-poncet, M. Wolf, D. Lasne, A. Bauters, P. Ffrench et al., Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: report of 12 cases, Intensive Care Med. août, vol.35, issue.8, pp.1449-53, 2009.
URL : https://hal.archives-ouvertes.fr/ujm-00440308

B. E. Lewis, D. E. Wallis, S. D. Berkowitz, W. H. Matthai, J. Fareed et al.,

, Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia. Circulation. 10 avr, vol.103, issue.14, pp.1838-1881, 2001.

B. E. Lewis, D. E. Wallis, F. Leya, M. J. Hursting, and J. G. Kelton, Argatroban Anticoagulation in Patients With Heparin-Induced Thrombocytopenia, ARCH INTERN MED, vol.163, p.8, 2003.

, Résumé des caractéristiques du produit -ARGATROBAN ACCORD 1 mg/mL, solution pour perfusion -Base de données publique des médicaments

D. Sur,

S. Guy, S. Kitchen, R. Maclean, and J. J. Van-veen, Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban, Int Jnl Lab Hem. déc, vol.37, issue.6, pp.834-877, 2015.

T. E. Warkentin, Heparin-induced thrombocytopenia: Current Opinion in Critical Care, déc, vol.21, issue.6, pp.576-85, 2015.

S. Guy, S. Kitchen, and J. J. Van-veen, Further evidence of the limitations of Activated Partial Thromboplastin Time to monitor Argatroban, Br J Haematol. févr, vol.180, issue.4, pp.594-601, 2018.

A. Alatri, A. Armstrong, A. Greinacher, A. Koster, S. A. Kozek-langenecker et al., Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy -A European Perspective, Thrombosis Research. avr, vol.129, issue.4, pp.426-459, 2012.

N. Vu, E. Jaynes, C. Chan, M. Dorsch, S. Pipe et al., Argatroban monitoring: aPTT versus chromogenic assay: Letter to the Editor, Am J Hematol. juin, vol.91, issue.6, pp.303-307, 2016.

L. Linkins, A. L. Dans, L. K. Moores, R. Bona, B. L. Davidson et al., Treatment and Prevention of Heparin-Induced Thrombocytopenia, Chest. févr, vol.141, issue.2, pp.495-530, 2012.

L. Linkins, G. Hu, and T. E. Warkentin, Systematic review of fondaparinux for heparin-induced thrombocytopenia: When there are no randomized controlled trials. Res Pract Thromb Haemost, vol.2, pp.678-83, 2018.

M. Kang, M. Alahmadi, S. Sawh, M. J. Kovacs, and A. Lazo-langner, Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study, Blood. 5 févr, vol.125, issue.6, pp.924-933, 2015.

A. Greinacher, Immunogenic but effective: the HIT-fondaparinux brain puzzler, J Thromb Haemost. déc, vol.9, issue.12, pp.2386-2394, 2011.

M. Schindewolf, J. Steindl, J. Beyer-westendorf, S. Schellong, P. M. Dohmen et al., Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia, Journal of the American College of Cardiology, vol.70, issue.21, pp.2636-2684, 2017.

M. Schindewolf, Fondaparinux in heparin-induced thrombocytopenia: A decade's worth of clinical experience, Res Pract Thromb Haemost. janv, vol.3, issue.1, pp.9-11, 2019.

T. E. Warkentin, Fondaparinux for Treatment of Heparin-Induced Thrombocytopenia: Too Good to Be True?, J Am Coll Cardiol, vol.28, issue.21, pp.2649-51, 2017.

F. Manji, T. E. Warkentin, J. Sheppard, and A. Lee, Fondaparinux cross-reactivity in heparininduced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban, Platelets, vol.2, issue.2020, pp.124-131

L. A. Linkins, T. E. Warkentin, M. Pai, S. Shivakumar, R. A. Manji et al., Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study, J Thromb Haemost, vol.14, issue.6, pp.1206-1216, 2016.

T. E. Warkentin, M. Pai, and L. Linkins, Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review, Blood, vol.31, issue.9, pp.1104-1117, 2017.

, Abstract-Tardy HIT Confirm.pdf

, protocole HIT Confirm.pdf. Annexes Annexe 1 : Diagnostic clinico-biologique du GIHP/GFHT